{
  "docId": "019de076-495e-7269-8bd5-c9a0e886c917",
  "docSlug": "a4fc5169399f8913c54f14d18031629c",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 59,
  "pageCount": 64,
  "prevPage": 58,
  "nextPage": 60,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "Highlights NXC-201's lower fludarabine dose and compares infusion timing across therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-495e-7269-8bd5-c9a0e886c917/59",
  "deckHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917",
  "deckJsonHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917.json",
  "deckAnchorHref": "/decks/019de076-495e-7269-8bd5-c9a0e886c917#slide-59",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.6,
        "x": 0.02,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Source: Berdeja JG, et al. Lancet. 2021; Frigault MJ, et al. Blood Adv. 2023; Munshi NC, et al. N Engl J Med. 2021; Asherie N, et al. Haematologica. 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6bdc443f-9e19-4c11-8384-f6724b61a5d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.96,
        "x": 0.02,
        "y": 0.315
      },
      "kind": "table",
      "text": "Comparison of NXC-201, Abecma, Carvykti, and CART-ddBCMA across lymphodepletion regimen, frequency, and infusion timing.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc1646d0-e4a7-4060-9530-33fef18775ca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.27,
        "x": 0.02,
        "y": 0.05
      },
      "kind": "title",
      "text": "Preconditioning Regimens",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "815cc116-e960-4817-9335-13c5c90311b0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "5fa336b4-0e22-4be4-8f83-1b4ea766a41b",
      "evidence": "table/data: Comparison of NXC-201, Abecma, Carvykti, and CART-ddBCMA across lymphodepletion regimen, frequency, and infusion timing.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}